Association of loss of heterozygosity with shorter survival in primary glioblastoma patients.
暂无分享,去创建一个
W. Papierz | P. Potemski | D. Jesionek-Kupnicka | R. Kordek | M. Bienkowski | M. Szybka | I. Zawlik | D. Jaskólski | D. Kulczycka-Wojdala | W. Skowronski
[1] K. Aldape,et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution , 2013, Modern Pathology.
[2] M. Karsy,et al. Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features. , 2012, Folia neuropathologica.
[3] P. Kleihues,et al. The Definition of Primary and Secondary Glioblastoma , 2012, Clinical Cancer Research.
[4] Karsten Wrede,et al. DMBT1 Homozygous Deletion in Diffuse Astrocytomas Is Associated With Unfavorable Clinical Outcome , 2012, Journal of neuropathology and experimental neurology.
[5] R. Mirimanoff,et al. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial , 2012, Acta Neuropathologica.
[6] M. Moskała,et al. Co-occurrence of MGMT gene promoter methylation and amplification of EGFR in glioblastoma , 2011 .
[7] P. Birner,et al. Expression of mutated isocitrate dehydrogenase-1 in gliomas is associated with p53 and EGFR expression. , 2011, Folia neuropathologica.
[8] K. Hoang-Xuan,et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2 , 2010, Neurology.
[9] R. McLendon,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[10] R. Prayson,et al. Chromosome 1p and 19q Deletions in Glioblastoma Multiforme , 2009, Applied immunohistochemistry & molecular morphology : AIMM.
[11] G. Reifenberger,et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[13] R. Delfini,et al. Cerebral glioblastoma with oligodendrogliomal component: analysis of 36 cases , 2009, Journal of Neuro-Oncology.
[14] P. Liberski,et al. Arrested neural and advanced mesenchymal differentiation of glioblastoma cells-comparative study with neural progenitors , 2009, BMC Cancer.
[15] P. Liberski,et al. High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations. , 2009, Cancer genetics and cytogenetics.
[16] L. Chimelli,et al. Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis , 2008, Virchows Archiv.
[17] Arie Perry,et al. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. , 2007, Archives of pathology & laboratory medicine.
[18] P. Rieckmann,et al. Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26) , 2006, BMC Cancer.
[19] S. Franceschi,et al. Correlation Among Pathology, Genotype, and Patient Outcomes in Glioblastoma , 2006, Journal of neuropathology and experimental neurology.
[20] K. Hoang-Xuan,et al. Prognostic impact of molecular markers in a series of 220 primary glioblastomas , 2006, Cancer.
[21] N. Sharpless,et al. INK4a/ARF: a multifunctional tumor suppressor locus. , 2005, Mutation research.
[22] P. Kleihues,et al. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. , 2005, Journal of neuropathology and experimental neurology.
[23] Paola Pisani,et al. Genetic Pathways to Glioblastoma , 2004, Cancer Research.
[24] Kenji Tada,et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. , 2003, Cancer research.
[25] Daniel J Brat,et al. Genetic Markers in Glioblastoma: Prognostic Significance and Future Therapeutic Implications: On: Impact of Genotype Morphology on the Prognosis of Glioblastoma. Schmidt MC Antweiler S, Urban N, et al. J Neuropathol Exp Neurol 2002;61:321–328. , 2003, Advances in anatomic pathology.
[26] Guido Reifenberger,et al. Pten signaling in gliomas. , 2002, Neuro-oncology.
[27] R. McLendon,et al. Molecular markers of prognosis in astrocytic tumors , 2002, Cancer.
[28] Andreas von Deimling,et al. Impact of Genotype and Morphology on the Prognosis of Glioblastoma , 2002, Journal of neuropathology and experimental neurology.
[29] K. Hoang-Xuan,et al. Glioblastomas with an Oligodendroglial Component: A Pathological and Molecular Study , 2001, Journal of neuropathology and experimental neurology.
[30] D. Louis,et al. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. , 2000, Journal of neurosurgery.
[31] Y. Yonekawa,et al. Loss of Heterozygosity on Chromosome 19 in Secondary Glioblastomas , 2000, Journal of neuropathology and experimental neurology.
[32] Jan Mollenhauer,et al. DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3–26.1 is deleted in malignant brain tumours , 1997, Nature Genetics.
[33] Y. Yonekawa,et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] M. Wigler,et al. PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.
[35] F. Zindy,et al. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest , 1995, Cell.
[36] V. Preedy,et al. European Organization for Research and Treatment of Cancer , 2010 .
[37] H. Armah. Prognostic Impact of Molecular Markers in a Series of 220 Primary GlioblastomasHouillier C, Lejeune J, Benouaich-Amiel A, et al (INSERM U711, Paris; Pierre and Marie Curie Univ, Paris; Group Hosp Pitie-Salpetriere, Paris) Cancer 106:2218–2223, 2006§ , 2008 .
[38] Takaaki Kirino,et al. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[39] A. Mukasa,et al. Correlation of Histology and Molecular Genetic Analysis of 1 p , 19 q , 10 q , TP 53 , EGFR , CDK 4 , and CDKN 2 A in 91 Astrocytic and Oligodendroglial Tumors 1 , 2002 .
[40] J. Kuratsu,et al. Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: correlation with patient age and survival. , 2001, Journal of neurosurgery.
[41] Yasuhiro Yonekawa,et al. Promoter Hypermethylation of the RB1 Gene in Glioblastomas , 2001, Laboratory Investigation.
[42] Stefano Colella,et al. Loss of Heterozygosity on Chromosome 10 Is More Extensive in Primary (De Novo) Than in Secondary Glioblastomas , 2000, Laboratory Investigation.